Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline

Experimental Neurology

Volumn 229, Issue 2, 2011, Pages 353-357

  Boyette Davis, J ^a   Dougherty, P M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Intraepidermal nerve fiber; Minocycline; Neuropathy; Oxaliplatin

Indexed keywords

CELL MARKER; MINOCYCLINE; OXALIPLATIN; PROTEIN PGP9.5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL LOSS; CONTROLLED STUDY; DRUG EFFICACY; HYPERALGESIA; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; INTRAEPIDERMAL NERVE FIBER; MALE; MECHANICAL STIMULATION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MALE; MINOCYCLINE; NERVE FIBERS; ORGANOPLATINUM COMPOUNDS; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; SKIN;

EID: 79956113018     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.02.019     Document Type: Article

References (40)

1. Argyriou A.A., Polychronopoulos P., Iconomou G., Koutras A., Makatsoris T., Gerolymos M.K., Gourzis P., Assimakopoulos K., Kalofonos H.P., Chroni E. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol. 2007, 46:1131-1137.
2. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 2008, 34:368-377.
3. Basu S., Sodhi A. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol. Cell Biol. 1992, 70(Pt 1):15-24.
4. Bennett G.J. Does a neuroimmune interaction contribute to the genesis of painful peripheral neuropathies?. Proc. Natl. Acad. Sci. USA 1999, 96:7737-7738.
5. Boyette-Davis J., Xin W., Zhang H., Dougherty P.M. Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011, 152:308-313.
6. Cata J.P., Weng H.-R., Dougherty P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006, 72:151-169.
7. Cata J.P., Weng H.R., Dougherty P.M. The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res. 2008, 1229:100-110.
8. Cavaletti G., Tredici G., Petruccioli M.G., Donde E., Tredici P., Marmiroli P., Minoia C., Ronchi A., Bayssas M., Etienne G.G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer 2001, 37:2457-2463.
9. Cho I.H., Chung Y.M., Park C.K., Park S.H., Li H.Y., Kim D., Piao Z.G., Choi S.Y., Lee S.J., Park K., Kim J.S., Jung S.J., Oh S.B. Systemic administration of minocycline inhibits formalin-induced inflammatory pain in rat. Brain Res. 2006, 1072:208-214.
10. Darst M., Al Hassani M., Li T., Yi Q.F., Travers J.M., Lewis D.A., Travers J.B. Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line. J. Immunol. 2004, 172:6330-6335.
11. de Gramont A. Rapid evolution in colorectal cancer: therapy now and over the next five years. Oncologist 2005, 10:4-8.
12. Dougherty P.M., Cata J.P., Cordella J.V., Burton A., Weng H.-R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109:132-142.
13. Gamelin L., Boisdron-Celle M., Delva R., Guerin-Meyer V., Ifrah N., Morel A., Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 2004, 10:4055-4061.
14. Gan X.H., Jewett A., Bonavida B. Activation of human peripheral-blood-derived monocytes by cis-diamminedichloroplatinum: enhanced tumoricidal activity and secretion of tumor necrosis factor-alpha. Nat. Immun. 1992, 11:144-155.
15. Keilhoff G., Schild L., Fansa H. Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in bioartificial nerve grafts lacking Wallerian degeneration. Exp. Neurol. 2008, 212:189-200.
16. Kennedy W.R., Wendelschafer-Crabb G., Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996, 47:1042-1048.
17. Lauria G., Lombardi R., Camozzi F., Devigili G. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology 2009, 54:273-285.
18. Ling B., Authier N., Balayssac D., Eschalier A., Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 2007, 128:225-234.
19. Louvet C., Andre T., Tigaud J.M., Gamelin E., Douillard J.Y., Brunet R., Francois E., Jacob J.H., Levoir D., Taamma A., Rougier P., Cvitkovic E., de Gramont A. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 2002, 20:4543-4548.
20. McArthur J.C., Stocks E.A., Hauer P., Cornblath D.R., Griffin J.W. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch. Neurol. 1998, 55:1513-1520.
21. Milligan E.D., Twining C., Chacur M., Biedenkapp J., O'Connor K., Poole S., Tracey K., Martin D., Maier S.F., Watkins L.R. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. 2003, 23:1026-1040.
22. Nikodemova M., Duncan I.D., Watters J.J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and I kappa B alpha degradation in a stimulus-specific manner in microglia. J. Neurochem. 2006, 96:314-323.
23. Nolano M., Simone D.A., Wendelschafer-Crabb G., Johnson T., Hazen E., Kennedy W.R. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999, 81:135-145.
24. Oaklander A.L. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 2001, 92:139-145.
25. Oaklander A.L., Rissmiller J.G., Gelman L.B., Zheng L., Chang Y.C., Gott R. Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain 2006, 120:235-243.
26. O'Brien J.M., Wewers M.D., Moore S.A., Allen J.N. Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion. A role for microtubules in the regulation of IL-1 beta production. J. Immunol. 1995, 154:4113-4122.
27. Pai K., Sodhi A. Effect of cisplatin, rIFN-Y, LPS and MDP on release of H2O2, O2- and lysozyme from human monocytes in vitro. Indian J. Exp. Biol. 1991, 29:910-915.
28. Petersen K.L., Rice F.L., Farhadi M., Reda H., Rowbotham M.C. Natural history of cutaneous innervation following herpes zoster. Pain 2010, 150:75-82.
29. Postma T.J., Benard B.A., Huijgens P.C., Ossenkoppele G.J., Heimans J.J. Long term effects of vincristine on the peripheral nervous system. J. Neurol. Onocol. 1993, 15:23-27.
30. Postma T.J., Vermorken J.B., Liefting A.J.M., Pinedo H.M., Heimans J.J. Paclitaxel-induced neuropathy. Ann. Oncol. 1995, 6:489-494.
31. Quasthoff S., Hartung H.-P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002, 249:9-17.
32. Raghavendra V., Tanga F., DeLeo J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 2003, 306:624-630.
33. Sakurai M., Egashira N., Kawashiri T., Yano T., Ikesue H., Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 2009, 147:165-174.
34. Scarpini E., De Riz M., Conti G., Scarlato G. Painful symptoms of diabetic neuropathy. G. Neuropsicofarmacologia 2001, 23:127-128.
35. Shun C.T., Chang Y.C., Wu H.P., Hsieh S.C., Lin W.M., Lin Y.H., Tai T.Y., Hsieh S.T. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain 2004, 127:1593-1605.
36. Siau C., Xiao W., Bennett G.J. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp. Neurol. 2006, 201:507-514.
37. Sorkin L.S., Xaio W.-H., Wagner R., Myers R.R. Tumour necrosis factor-α induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997, 81:255-262.
38. Wolf J., Richardson P.G., Schuster M., LeBlanc A., Walters I.B., Battleman D.S. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin. Adv. Hematol. Oncol. 2008, 6:755-760.
39. Zaks-Zilberman M., Zaks T.Z., Vogel S.N. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 2001, 15:156-165.
40. Zimmermann M. Ethical guidelines for investigators of experimental pain inconscious animals. Pain 1983, 16:109-110.